During the last session, Candel Therapeutics Inc (NASDAQ:CADL)’s traded shares were 0.45 million, with the beta value of the company hitting -0.92. At the end of the trading day, the stock’s price was $4.81, reflecting an intraday gain of 1.05% or $0.05. The 52-week high for the CADL share is $14.60, that puts it down -203.53 from that peak though still a striking 21.21% gain since the share price plummeted to a 52-week low of $3.79. The company’s market capitalization is $236.98M, and the average trade volume was 1.13 million shares over the past three months.
Candel Therapeutics Inc (CADL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CADL has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.
Candel Therapeutics Inc (NASDAQ:CADL) trade information
Candel Therapeutics Inc (CADL) registered a 1.05% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.05% in intraday trading to $4.81, hitting a weekly high. The stock’s 5-day price performance is -8.90%, and it has moved by -5.59% in 30 days. Based on these gigs, the overall price performance for the year is -49.84%.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -43.86%. While earnings are projected to return 13.60% in 2025, the next five years will return 16.34% per annum.
CADL Dividends
Candel Therapeutics Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 0.82 million shares, is of BLACKROCK INC.’s that is approximately 2.7548% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $5.1 million.
Also, the Mutual Funds coming in first place with the largest holdings of Candel Therapeutics Inc (CADL) shares are Fidelity Select Portfolios-Biotechnology Portfolio and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Mar 31, 2025 indicates that Fidelity Select Portfolios-Biotechnology Portfolio owns about 5.54 shares. This amounts to just over 11.25 percent of the company’s overall shares, with a $26.67 million market value. The same data shows that the other fund manager holds slightly less at 866.65, or about 1.76% of the stock, which is worth about $4.17 million.
